- Home
- SEED vs ASBP Comparison
SEED vs ASBP Comparison
Compare SEED & ASBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SEED | ASBP |
|---|---|---|
| Founded | 1997 | 2021 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.8M | 7.6M |
| IPO Year | 2005 | N/A |
Fundamental Metrics
Financial Performance| Metric | SEED | ASBP |
|---|---|---|
| Price | $1.04 | $1.44 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 24.8K | ★ 550.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.82 | $0.05 |
| 52 Week High | $2.49 | $2.45 |
Technical Indicators
Market Signals| Indicator | SEED | ASBP |
|---|---|---|
| Relative Strength Index (RSI) | 39.76 | 53.71 |
| Support Level | $0.97 | $0.20 |
| Resistance Level | $1.21 | $1.63 |
| Average True Range (ATR) | 0.08 | 0.16 |
| MACD | -0.00 | -0.05 |
| Stochastic Oscillator | 8.00 | 53.49 |
Price Performance
Historical ComparisonAbout SEED Origin Agritech Limited
Origin Agritech Ltd is a Chinese agricultural technology company operating in the PRC including seed research and development activities featured in crop seed breeding and genetic improvement. The company's phytase corn was the first transgenic corn to receive the Bio-Safety Certificate from China's Ministry of Agriculture. Origin has established a robust biotechnology seed pipeline including products with glyphosate tolerance and pest resistance (Bt) traits.
About ASBP Aspire Biopharma Holdings Inc.
Aspire Biopharma Holdings Inc developing next-generation absorption of medicine that will have an impact on the opioid crisis. The group engaged in the business of developing and marketing disruptive technology for novel delivery mechanisms for do-no-harm drugs. Its nanotechnology drug formulation directly targets pain and inflammation bypassing the gastrointestinal tracts.